Capricor Therapeutics
Chemicals & Related Products · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10865 Road to the Cure Ste 150, San Dieg...Phone Number
(858) 727-1755Website
www.capricor.comRevenue
$11.1 MillionStock Symbol
CAPRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative therapeutic approaches by leveraging its expertise in regenerative medicine, cellular therapies, and exosome technology to address significant unmet medical needs.Explore more
Capricor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Capricor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Capricor Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Capricor Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Capricor Therapeutics has new funding data
Product Launch: Get notified when Capricor Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Capricor Therapeutics
Check out if Capricor Therapeutics is spiking on competitors!
Capricor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Capricor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Capricor Therapeutics
Compare insights from companies similar to Capricor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$196.1M
201-500
Public
$466M
1990
Bryan RidgellSenior Vice President, Portfolio and Project Management, and Chief of Staff
Company Profile Activity
Activity Insights
Capricor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Capricor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Capricor Therapeutics.
Capricor Therapeutics financials insights
Gather financial insights about Capricor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2024
Private Equity
$35M
Capricor Therapeutics Tech Stack
A closer look at the technologies used by Capricor Therapeutics
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Facilities Relocation/Expansion, Leasing, Manufacturing Operations
Person-Based
Stake & Stock Ownership, Finance
Open Position
Open Position
Open Position
Capricor Therapeutics News & Media
CAPR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 29, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their OptionsCAPRICOR THERAPEUTICS, INC. (CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
Capricor Therapeutics Shareholders Between December 17, 2025 and July 6, 2026 - Contact Bernstein Liebhard For More Information Regarding LawsuitCapricor (CAPR) Closed 58% Higher on an FDA Lifeline. Is Approval Really Back on Track?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) closed 58% higher at $6.65 on August 14 after the company said the FDA was willing to review an amendment containing 24-month data for deramiocel, its Duchenne muscular dystrophy treatment. The shares had traded as much as 94% above the previous close before surrendering part of the gain. The rebound recovered […]ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CAPR
NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), of the important September 28, 2026 lead plaintiff deadline.
Read more news
Top Chemicals & Related Products Companies
See more top companies
Frequently Asked Questions Regarding Capricor Therapeutics
Sign Up For FreeTo access detailed company insights
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative... Read More
